Dr. Rosenfield is an interventional cardiologist and vascular specialist performing complex cardiac and vascular interventions. He is Section Head for Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital. He earned a masters degree in Health Care Delivery Science from Dartmouth College. In addition to being a master clinician and interventionalist, Dr. Rosenfield has dedicated much of his career to educating fellows, residents, students, and colleagues. He is the recipient of the distinguished Laennec award for his outstanding teaching and mentorship. He is also a researcher and clinical trialist. He designed and served as national principle investigator for several landmark studies, including Aspire 2, Levant 2, Superb, ACT 1, and NIH BEST-CLI trial. He is a leader in the cardiovascular world, having been elected to the Board of Governors of American College of Cardiology, immediate past-President of the MA ACC Chapter, and immediate past-President of the Society for Cardiovascular Angiography and Interventions (SCAI). Dr. Rosenfield is a founding member of VIVA, a 501c3 organization, and sits on its board of directors. At Massachusetts General Hospital, he is the Medical director of the PERT Program, which he founded with his colleagues; he also founded the National PERT Consortium, a 501c3 organization dedicated to improving management, outcomes, and awareness of Pulmonary Embolism, and he served as its initial President; he remains a member of the PERT Consortium Executive Committee.